Institute of Liver Studies, King's College Hospital, London, UK.
Transpl Int. 2013 Nov;26(11):1070-9. doi: 10.1111/tri.12164.
Recent data suggest an association of serum ferritin (SF) with waiting list (WL) and postliver transplant (LT) outcomes. To assess the predictive capacity of SF on pre- and post-LT outcomes, and to identify whether recipient or donor liver siderosis is associated with post-LT survival; a retrospective analysis of 1079 patients assessed for first LT, 2000-2007 was performed. Iron deposition in the liver tissue was assessed using a semi-quantitative grading system. Median age was 54 (18-82) years and 67% were male. Seventeen per cent had hepatocellular carcinoma (HCC). Median Model for End-stage Liver Disease MELD score was 14 (6-40), ferritin was 174 μg/l (4-4597) with 36.5% had a SF ≥ μg/l. Age (OR = 1.028) and MELD score (OR = 1.158) were independently associated with WL mortality (P < 0.001), whilst SF was not (P = NS). Age (OR = 1.018), HCC (OR = 1.542) and cold ischemia time (CIT) ≥ 10 h (OR = 1.418) were independently associated with post-LT survival (P < 0.05). Explant siderosis grade <2 was seen in 376 (71.7%) patients. Patients with explant siderosis grade ≥ 2 had inferior 12-month post-LT survival (P = 0.030). Presence of graft siderosis (15.8% of patients) was not associated with survival. In conclusion, we found a limited role for SF as a prognostic indicator for pre- or post-transplant survival.
最近的数据表明,血清铁蛋白(SF)与等待名单(WL)和肝移植后(LT)的结果有关。为了评估 SF 在 LT 前和 LT 后的结果预测能力,并确定受体或供体肝铁沉积是否与 LT 后生存率相关;对 2000-2007 年评估的 1079 例首次 LT 患者进行了回顾性分析。使用半定量分级系统评估肝组织中的铁沉积。中位年龄为 54 岁(18-82 岁),67%为男性。17%患有肝细胞癌(HCC)。中位终末期肝病模型 MELD 评分 14(6-40),铁蛋白 174μg/l(4-4597),36.5%的 SF≥μg/l。年龄(OR=1.028)和 MELD 评分(OR=1.158)与 WL 死亡率独立相关(P<0.001),而 SF 则没有(P=NS)。年龄(OR=1.018)、HCC(OR=1.542)和冷缺血时间(CIT)≥10 h(OR=1.418)与 LT 后生存率独立相关(P<0.05)。376 例(71.7%)患者的移植前铁沉积分级<2。移植前铁沉积分级≥2 的患者 LT 后 12 个月生存率较低(P=0.030)。移植物铁沉积的存在(15.8%的患者)与生存率无关。总之,我们发现 SF 作为 LT 前或 LT 后生存的预后指标的作用有限。